Last year was full of upheaval and change. The global economy slowed throughout 2001 and the future of science funding seemed more precarious. Numerous pharmaceutical companies laid off thousands of employees in an effort to stave off even more dire consequences. And that was all before 11 September 2001. Much has been written since then about how the world and our place in it has shifted. But whether or not permanent alterations in national or international moods or behavior occur as a direct result of the terror attack, one thing is certain: it reminded many of us of just how fragile and illusory life can be. And before we could completely come to grips with that tragedy, another struck -the death of Don Wiley, an outstanding structural biologist from Harvard University whose group, together with Jack Strominger's laboratory, elucidated the structures of both class I and class II histocompatibility antigens. His contributions laid the foundation upon which more than a decade of immunological revelations now rest. His piercing intellect and talent for solving those structures that reveal the most fundamental insights will be greatly missed. For a glimpse into the collaboration that bore these fruits, read the reminiscence by Jack Strominger in the Commentary section of this issue.
The message being hammered home by these events is that our productive years are incredibly precious and can be startlingly short. Now that we are into a new year, it may be worth a few minutes of our time to examine our own scientific choices. Not all immunological enigmas are created equal. To be most productive and get the greatest satisfaction out of doing research, the goal of significantly advancing the field cannot stray from one's sight. Is the immunology community channeling sufficient effort into following the most interesting leads and making the best use of our resources and time?
The number of points in immunology that are still not understood are many. Which are worth investigating? Pursuit of the most central problems moves the field the farthest. Recognition of the key questions and the willingness to pursue them takes both wisdom and the courage to take chances. The biggest breakthroughs often come when following trails others regard as misguided or have ignored. It is the trail that no one has been on that's the most interesting, and the hardest to find. One needs the skill to discern the difference between the trivial discrepancy and the profound discordance. Bench scientists gather data and daily make decisions concerning which investigative paths to pursue. But when confronted with experiments that don't come out as predicted, the most fruitful direction usually isn't easy to determine.
With all the effort that investigative science entails, and with all of the financial and temporal resources put into it, one would hope that the right direction were chosen frequently. However, poor technique, unanticipated flaws in the setup, or expediency often color decisions. We all know of research (of course done by others) that prompts much head shaking and the question, why? What did they think they would gain from characterizing that unphysiological phenomenon, or those manipulations of that system? Other work makes no effort to connect the reader with the larger question that supposedly drove the research, or uses an inappropriate approach. Another body of publications result from the "this type of work can get funded" mentality. When faced with the choice of risky research with no guaranteed return for the effort versus doing the next expected step, too often the latter wins out, as a matter of expediency. Many unanticipated results are gathering dust in lab notebooks (or becoming inaccessible on outmoded computer disks) due to a lack of appreciation of their value, or because grants would be difficult to come by for investigation of such novel hypotheses as the anomalous preliminary data inspire. And yet, these data are often the source of breakthroughs. How many times have promising lines of inquiry sidled up to within a hair's breadth of the answer, but instead, the unusual data were squeezed into the old paradigm, with no recognition that the data could lead to a better explanation that could illuminate even more of the field?
It seems that lately the balance in immunology has tipped: too much effort is funneling into the "done for the sake of the grant" category and less and less into pursuit of the very risky, yet tantalizing, lead. This may be the fault of the current system of research support, but in order to get out of this safe but inefficient (as a means of advancing the field) rut, we must first recognize that we may be in it. As can be seen from the example of Don Wiley's career trajectory, if the science isn't fresh, fun and innately interesting, it isn't worth doing. Don Wiley had an unerring sense of the important; his unwillingness to pursue anything less should remain a lasting message for us all.
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